EHA 2018: Nilotinib and Lower-Intensity Chemotherapy Promising Treatment for Ph+ Acute Lymphoblastic Leukemia
Treatment associated with a high major molecular response rate and positive short-term outcome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.